EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Medication‐Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab

Laura Sisalli, Francesco Giordano, Andrea Chiacchio, Alfonso Acerra, Mario Caggiano iD

Case Reports in Dentistry · 2023-01 · 2023 (1)

DOI: 10.1155/2023/5544285 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Dentistry, online erschienen am 15.12.2023. Verfasst von Laura Sisalli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Surgery and Dentistry, "Scuola Medica Salernitana", Via Allende, Baronissi, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medication‐related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction characterized by progressive bone destruction and necrosis of mandibular and/or maxillary jaw bone that occurs in patients undergoing treatments with antiresorptive drugs such as bisphosphonates or denosumab, antiangiogenic agents such as bevacizumab, or other kinds of monoclonal antibodies such as rituximab and ipilimumab, for different oncologic and nononcologic diseases. The aim of this study was to report a case of MRONJ in a patient affected by rheumatoid arthritis disease in treatment with adalimumab. Case Presentation . A 70‐year‐old female patient affected by rheumatoid arthritis (RA), who had been undergoing adalimumab (40 mg subcutaneous injection) every two weeks for 5 years, with no history of antiresorptive or antiangiogenic agent administration, came to our attention for intraoral necrotic bone exposures of the anterior mandible. After drug withdrawal and antibiotic cycles, the patient underwent surgical treatment with bone resection and debridement of necrotic tissues. After an observation period of 8 months, a complete healing without signs of recurrence was detected.

Conclusions

Based on this study, a correlation between adalimumab and MRONJ is possible. Therefore, we believe that an oral cavity examination should be done in every patients, before starting therapy with adalimumab, to possibly avoid MRONJ onset. Further studies are required to confirm the role of adalimumab in MRONJ.

Autor:innen und Institutionen

  • Department of Medicine Surgery and Dentistry, "Scuola Medica Salernitana", Via Allende, Baronissi, Italy.

ORCID-Profile: Mario Caggiano

Zitieren

APA

Sisalli, L., Giordano, F., Chiacchio, A., Acerra, A., & Caggiano, M. (2023). Medication‐Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab. Case Reports in Dentistry, 2023(1). https://doi.org/10.1155/2023/5544285

Vancouver

Sisalli L, Giordano F, Chiacchio A, Acerra A, Caggiano M. Medication‐Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab. Case Reports in Dentistry. 2023;2023(1). doi:10.1155/2023/5544285

BibTeX
@article{Sisalli2023,
  author = {Sisalli, Laura and Giordano, Francesco and Chiacchio, Andrea and Acerra, Alfonso and Caggiano, Mario},
  title = {Medication‐Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab},
  journal = {Case Reports in Dentistry},
  year = {2023},
  volume = {2023},
  number = {1},
  doi = {10.1155/2023/5544285}
}
Kostenlos starten →